Presentations
Egetis – Corporate Presentation November 2023
November 8, 2023
Egetis – Corporate Presentation October 2023
October 23, 2023
Egetis – Corporate Presentation August 2023
August 30, 2023
Egetis – Corporate Presentation July 2023
July 7, 2023
Egetis Presentation – Investor and Analyst Webinar 29 June 2023
June 29, 2023
Egetis – Corporate Presentation June 2023
May 30, 2023
Egetis – Corporate Presentation May 2023
May 16, 2023
Egetis Corporate Presentation February 2023
February 23, 2023
Egetis Corporate Presentation January 2023
January 17, 2023
Egetis Corporate Presentation December 2022
December 20, 2022
Egetis Corporate Presentation November 2022
November 28, 2022
Redeye interview with CEO Nicklas Westerholm
November 24, 2022
Egetis Corporate Presentation October 2022
October 18, 2022
Egetis Corporate Presentation September 2022
September 28, 2022
Egetis – Corporate Presentation August 2022
August 22, 2022
Redeye interview with CEO after Q2 report
August 19, 2022
Pareto interview with Peder Walberg and Nicklas Westerholm
July 25, 2022
Nicklas Westerholm presenting at ABGSC Life Science Summit
May 18, 2022
Egetis – Corporate Presentation May 2022
May 17, 2022
Peder Walberg presenting at Redeye Orphan Drugs event
April 27, 2022
Handelsbanken Healthy Hour
March 23, 2022
Redeye interview with CEO after Q4 report 17 February 2022
February 17, 2022
Webcast regarding US regulatory path
January 18, 2022
Webcast regarding marketing authorisation application for Emcitate®
December 13, 2021
Redeye life science day
November 11, 2021
Redeye interview with the CEO in connection with the Q3 report
November 4, 2021
Interview with Peder Walberg at Pareto, operative director of the board and founder of Rare Thyroid Therapeutics (in Swedish)
October 28, 2021
Presentation at Penser
30 september, 2021
The Pareto Healthcare conference presentation
September 1, 2021
ABGSC Life Science Summit
May 25
Erik Penser Bank – Commercialization of pharmaceuticals
May 6, 2021
Aktiedagen (in Swedish)
May 4
Redeye Orphan Drugs
April 28, 2021
Interview with Dr Thomas Lönngren, nominated CoB and CEO Nicklas Westerholm
April 1, 2021
Interview with CEO Nicklas Westerholm at Redeye
February 18, 2021
Interview with CEO Nicklas Westerholm in Pareto TV
February 1, 2021
Company investor and analyst presentation – acquisition of RTT
October 5, 2020
Acquisition of Rare Thyroid Therapeutics – Interview at Redeye
October 5, 2020
Egetis and RTT agree to join forces
October 5, 2020
Pareto Healthcare Seminar – Company presentation
September 2, 2020